There are instances, including our own studies, of both genetic and chemical targeting of PRDX1 in such malignancies as oral cancer,38 Burkitt lymphoma8 or cervical cancer.39 Combination of PRDX1 targeting and a prooxidant agent menadione, that induces mostly superoxide production, has also been reported in the past.24 However, the significant advantage of the current study is that it pinpoints the unique role for PRDX1, in comparison with PRDX2, as a superior enzyme governing the redox resistance against the exogenous oxidative offence in breast cancer. The gene discussed is PRDX2; the disease is breast cancer.